Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells

Journal of Endocrinological Investigation

Volumn 35, Issue 4, 2012, Pages 365-371

  Benvenuti, S ^a   Cellai, I ^a   Luciani, P ^a   Deledda, C ^a   Saccardi, R ^b   Mazzanti, B ^b   Dal Pozzo, S ^b   Serio, M ^a   Peri, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Androgens; Bone; Estrogens; Osteoporosis; Thiazolidinediones

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENISTEIN; METRIBOLONE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUERCETIN; ROSIGLITAZONE; TESTOSTERONE;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; OSTEOBLAST; PROTEIN EXPRESSION;

ADIPOCYTES; ADIPOGENESIS; ANDROGENS; CELL DIFFERENTIATION; CELLS, CULTURED; ESTROGENS; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; THIAZOLIDINEDIONES;

EID: 84863959602     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7739     Document Type: Article

References (39)

1. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91: 3349-54. (Pubitemid 44402103)
2. Grey A, Bolland M, Gamble G et al. The peroxisome proliferators-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92: 1305-10. (Pubitemid 46556402)
3. Gruntmanis U, Fordan S, Ghayee HK, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int. 2010 86: 343-9.
4. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355: 2427-43. (Pubitemid 44903747)
5. Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM Thiazolidine diones and fractures in men and women. Arch Intern Med 2009, 169: 1395-402.
6. Mancini T, Mazziotti G, Doga M, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 2009, 45: 784-8.
7. Douglas IJ, Evans SJ, Pocock S, Smeeth L. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009, 6: e1000154.
8. Bilik D, McEwen LN, Brown MB, et al Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab. 2010, 95: 4560-5.
9. Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95: 592-600.
10. Sorocéanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC. Rosiglitazone impacts negatively on bone by promoting osteblast/ osteocyte apoptosis. J Endocrinol 2004, 183: 203-16. (Pubitemid 40124657)
11. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 2005, 146: 1226-35. (Pubitemid 40289310)
12. Lecka-Czernik B Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep 2010, 8: 178-84.
13. Viccica G, Francucci CM, Marcocci C. The role of PPARγ for the osteoblastic differentiation. J Endocrinol Invest 2010, 33 (7 Suppl): 9-12.
14. Benvenuti S, Cellai I, Luciani P et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007, 30: RC26-30. (Pubitemid 350238195)
15. Gurkan UA, Akkus O. The mechanical environment of bone marrow: a review. Ann Biomed Eng 2008, 36: 1978-91.
16. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003, 144: 5081-8. (Pubitemid 37378423)
17. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008, 296: 32-40.
18. Benvenuti S, Saccardi R, Luciani P, et al. Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. Exp Cell Res 2006, 312: 2592-04.
19. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284: 143-7. (Pubitemid 29282067)
20. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8: 315-7. (Pubitemid 44269669)
21. Venken K, Callewaert F, Boonen S, Vanderschueren D. Sex hormones, their receptors and bone health. Osteoporos Int 2008, 19: 1517-25.
22. Imai Y, Kondoh S, Kouzmenko A, Kato S. Regulation of bone metabolism by nuclear receptors. Mol Cell Endocrinol 2009, 310: 3-10.
23. Vandenput L, Ohlsson C. Estrogens as regulators of bone health in men. Nat Rev Endocrinol 2009, 5: 437-43.
24. Vanderschueren D, Gaytant J, Boonen S, Venken K Androgens and bone. Curr Opin Endocrinol Diabetes Obes 2008, 15: 250-4. (Pubitemid 351595190)
25. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004, 25: 389-425. (Pubitemid 38786452)
26. Patisaul HB. Phytoestrogen action in the adult and developing brain. J Neuroendocrinol 2005, 17: 57-64. (Pubitemid 40372071)
27. Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Löwik CW. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2003, 278: 962-7. (Pubitemid 36790772)
28. Heim M, Frank O, Kampmann G, et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 2004, 145: 848-59. (Pubitemid 38183829)
29. Hirota K, Morikawa K, Hanada H, et al. Effect of genistein and daidzein on the proliferation and differentiation of human preadipo cyte cell line. J Agric Food Chem 2010, 58: 5821-7.
30. Park HJ, Della-Fera MA, Hausman DB, Rayalam S, Ambati S, Baile CA. Genistein inhibits differentiation of primary human adipocytes. The Journal of Nutritional Biochemistry 2009, 20: 140-8.
31. Berberoglu Z, Yazici AC, Demirag NG. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol (Oxf) 2010, 73: 305-12.
32. Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother 2007, 7: 1549-64. (Pubitemid 350106834)
33. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. Mol Nutr Food Res 2009, 53: 1084-97.
34. Coxam V. Phyto-oestrogens and bone health. Proc Nutr Soc 2008, 67: 184-95. (Pubitemid 351543400)
35. Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause 2008, 15: 748-57.
36. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of phytoestrogens: a meta-analysis of randomized trials. Am J Med 2009, 122: 939-46.
37. Compston JE Sex steroids and bone. Physiol Rev 2001, 81: 419-47. (Pubitemid 32096180)
38. Kawano H, Sato T, Yamada T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 2003, 100: 9416-21. (Pubitemid 37033943)
39. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall, Williams LK Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 592-600.